Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Empagliflozin on Left Ventricular Volumes in Heart Failure With Reduced Ejection Fraction
IRCT20211219053450N1Phase 3Completed
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of empagliflozin in heart failure with reduced ejection fraction (HFrEF), type 2 diabetes mellitus (T2DM) and prediabetes, sponsored by Ahvaz Jundishapur University of Medical Sciences. Started Jul 2022; status: completed.
02
Drugs
empagliflozin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)type 2 diabetes mellitus (T2DM)prediabetes
Beyond the preview
Go deeper on IRCT20211219053450N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20211219053450N1.